Managing Hodgkin lymphoma – a world view (from ISHL 2016)
by Christine Clark ISHL 2016 Professor Joseph Connors (Vancouver) speaks about the session at ISHL10 where a world view of the management of Hodgkin lymphoma was discussed. There… read more.
by Christine Clark ISHL 2016 Professor Joseph Connors (Vancouver) speaks about the session at ISHL10 where a world view of the management of Hodgkin lymphoma was discussed. There… read more.
Survival was more than 2 years shorter in breast, prostate cancers. Patients with rheumatoid arthritis (RA) had a 40% to 50% increased mortality risk if they developed breast… read more.
Consolidation and maintenance therapy for multiple myeloma: is it the new standard? Professor Antonio Palumbo (University of Turin, Italy) and Professor Paul Richardson (Harvard Medical School, Boston,… read more.
Preventing clonal evolution in multiple myeloma – evidence from clinical trials by Maria Dalby Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution… read more.
How monoclonal antibodies will change the treatment of multiple myeloma by Maria Dalby Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Meletios Dimopoulos, University of Athens School of… read more.
by Bruce Sylvester: Researchers from a randomized phase III trial report that addition of temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide,… read more.
by Bruce Sylvester: Anti-PD-L1 immunotherapy atezolizumab (TECENTRIQ) has shown efficacy in previously untreated patients with advanced bladder cancer who are ineligible for standard treatment with cisplatin.
by Bruce Sylvester: Investigative rovalpituzumab tesirine (Rova-T) appears to be safe and shows efficacy in treating advanced small cell lung cancer (SCLC), researchers reported in June, 2016 at… read more.
by Bruce Sylvester: A follow-up evaluation of subjects from the phase 1b trial (KEYNOTE-001) of newly diagnosed and previously treated patients with advanced melanoma revealed a 40% survival… read more.
Professor Karl Peggs, University College, London. by Christine Clark: There are numerous regimens for salvage treatment of Hodgkin lymphoma and all are associated with an overall response rate… read more.
Rethinking risk for better outcomes in ASCT by Christine Clark Dr Craig Moskowitz, Memorial Sloan Kettering Cancer Center, NY, USA. Patient populations are changing – before 2010 all… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.